$1.04 Billion is the total value of Sarissa Capital Management LP's 14 reported holdings in Q1 2021. The portfolio turnover from Q4 2020 to Q1 2021 was 16.7% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| IRWD | Buy | IRONWOOD PHARMACEUTICALS INC | $183,240,000 | +14.6% | 16,390,000 | +16.7% | 17.56% | +7.6% |
| BIIB | BIOGEN INC | $179,879,000 | +14.2% | 643,000 | 0.0% | 17.24% | +7.3% | |
| GILD | New | Gilead Sciences Inc | $174,332,000 | – | 2,697,400 | +100.0% | 16.71% | – |
| ALKS | Alkermes PLC | $148,506,000 | -6.4% | 7,950,000 | 0.0% | 14.24% | -12.1% | |
| ALXN | Sell | Alexion Pharmaceuticals Inc | $99,458,000 | -20.2% | 650,440 | -18.5% | 9.53% | -25.1% |
| BCRX | Sell | BioCryst Pharmaceuticals Inc | $77,675,000 | +27.5% | 7,637,700 | -6.6% | 7.44% | +19.8% |
| INVA | INNOVIVA INC | $76,647,000 | -3.6% | 6,414,000 | 0.0% | 7.35% | -9.4% | |
| MRSN | Buy | MERSANA THERAPEUTICS INC | $64,810,000 | -16.8% | 4,005,600 | +36.9% | 6.21% | -21.9% |
| VOR | New | VOR BIOPHARMA INC | $30,472,000 | – | 707,010 | +100.0% | 2.92% | – |
| SRSAW | SARISSA CAPITAL ACQUISITN COw exp 10/23/202 | $4,999,000 | 0.0% | 3,333,333 | 0.0% | 0.48% | -6.1% | |
| RGLS | REGULUS THERAPEUTICS INC | $2,888,000 | +15.6% | 1,851,851 | 0.0% | 0.28% | +8.6% | |
| MRTX | MIRATI THERAPEUTICS INC | $171,000 | -21.9% | 1,000 | 0.0% | 0.02% | -27.3% | |
| JAZZ | Sell | JAZZ PHARMACEUTICALS PLC | $164,000 | -99.9% | 1,000 | -99.9% | 0.02% | -99.9% |
| ICPT | INTERCEPT PHARMACEUTICALS INC | $21,000 | -8.7% | 950 | 0.0% | 0.00% | 0.0% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-05-17
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| BIOGEN INC. | 32 | Q3 2023 | 37.1% |
| INNOVIVA INC. | 29 | Q3 2023 | 19.5% |
| IRONWOOD PHARMACEUTICALS INC. | 24 | Q3 2023 | 24.2% |
| ABBVIE INC. | 23 | Q2 2020 | 24.4% |
| MEDICINES CO. | 20 | Q4 2019 | 33.9% |
| MERSANA THERAPEUTICS INC. | 19 | Q3 2023 | 7.9% |
| ALKERMES PLC | 16 | Q3 2023 | 43.7% |
| INTERCEPT PHARMACEUTICALS INC. | 15 | Q2 2021 | 10.7% |
| BIOCRYST PHARMACEUTICALS INC | 14 | Q3 2023 | 7.4% |
| VIVUS INC | 14 | Q1 2017 | 8.8% |
View Sarissa Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Alkermes plc. | August 24, 2023 | 8,323,400 | 5.0% |
| Innoviva, Inc. | May 15, 2023 | 6,904,000 | 10.5% |
| IRONWOOD PHARMACEUTICALS INC | March 01, 2021 | 14,890,000 | 9.3% |
| Iterum Therapeutics plcSold out | February 12, 2021 | 0 | 0.0% |
| BIOCRYST PHARMACEUTICALS INC | January 25, 2021 | 8,844,000 | 5.0% |
| Mersana Therapeutics, Inc. | January 25, 2021 | 3,770,000 | 5.5% |
| MEDICINES CO /DESold out | January 07, 2020 | 0 | 0.0% |
| Regulus Therapeutics Inc. | January 03, 2020 | 7,935,322 | 29.4% |
| NOVELION THERAPEUTICS INC. | November 09, 2018 | 909,296 | 4.6% |
| APRICUS BIOSCIENCES, INC. | September 05, 2018 | 1,152,455 | 4.8% |
View Sarissa Capital Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-03-19 |
| 13F-HR | 2024-02-14 |
| 4 | 2023-12-19 |
| SC 13D/A | 2023-12-05 |
| 13F-HR | 2023-11-14 |
| 4 | 2023-09-19 |
| SC 13D/A | 2023-09-05 |
| SC 13D/A | 2023-08-24 |
| 13F-HR | 2023-08-14 |
| DFAN14A | 2023-06-28 |
View Sarissa Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.